Evidence map›Paper›PMID 35423057›Full record

ReviewRSC advances2020

Microfluidics for core-shell drug carrier particles - a review.

Sepideh Yazdian Kashani, Amir Afzalian, Farbod Shirinichi, Mostafa Keshavarz Moraveji

Abstract readReview
In one paragraph

Review in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Droplet-Based Microfluidics: Applications in Pharmaceuticals.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sepideh Yazdian KashaniDepartment of Chemical Engineering, Amirkabir University of Technology (Tehran Polytechnic) 1591634311 Tehran Iran moraveji@aut.ac.ir +98 21 64543182.ORCID https://orcid.org/0000-0001-5077-9954
Amir AfzalianDepartment of Chemical Engineering, Amirkabir University of Technology (Tehran Polytechnic) 1591634311 Tehran Iran moraveji@aut.ac.ir +98 21 64543182.
Farbod ShirinichiDepartment of Chemical Engineering, Amirkabir University of Technology (Tehran Polytechnic) 1591634311 Tehran Iran moraveji@aut.ac.ir +98 21 64543182.
Mostafa Keshavarz MoravejiDepartment of Chemical Engineering, Amirkabir University of Technology (Tehran Polytechnic) 1591634311 Tehran Iran moraveji@aut.ac.ir +98 21 64543182.ORCID https://orcid.org/0000-0003-4891-340X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Core-shell drug-carrier particles are known for their unique features. Due to the combination of superior properties not exhibited by the individual components, core-shell particles have gained a lot of interest. The structures could integrate core and shell characteristics and properties. These particles were designed for controlled drug release in the desired location. Therefore, the side effects would be minimized. So, these particles' advantages have led to the introduction of new methods and ideas for their fabrication. In the past few years, the generation of drug carrier core-shell particles in microfluidic chips has attracted much attention. This method makes it possible to produce particles at nanometer and micrometer levels of the same shape and size; it usually costs less than other methods. The other advantages of using microfluidic techniques compared to conventional bulk methods are integration capability, reproducibility, and higher efficiency. These advantages have created a positive outlook on this approach. This review gives an overview of the various fluidic concepts that are used to generate microparticles or nanoparticles. Also, an overview of traditional and more recent microfluidic devices and their design and structure for the generation of core-shell particles is given. The unique benefits of the microfluidic technique for core-shell drug carrier particle generation are demonstrated.

Identifiers

PMID35423057
PMCPMC8691093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.